MedTrace Logo

EFFICACY OF ANSA (Experimental Drug) & CRAN MAX (Control Drug) SACHET

NCT05572268 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-10-07

No results posted yet for this study

Summary

I

This clinical trial aims to VIVO AND IN VITRO COMPARATIVE STUDY ON EFFICACY OF ANSA (experimental drug) \& CRAN MAX (control drug) SACHET IN UNCOMPLICATED UTI in females. The main question\[s\] it aims to answer are:

• Hypothesis I ANSA is an effective therapy for uncomplicated UTI treatment and inhibits or kills E.coli and other organisms in vitro and in vivo Null Hypothesis ANSA is not an effective therapy for uncomplicated UTI treatment and couldn't inhibit or kill E.coli and other organisms in vitro and in vivo Hypothesis II Cran Max is an effective therapy for uncomplicated UTIs and inhibits or kills E.coli and other organisms in vitro and in vivo Null Hypothesis Cran Max is not an effective therapy for uncomplicated UTI treatment and couldn't inhibit or kill E.coli and other organisms in vitro and in vivo

Conditions

  • Treatment Compliance

Interventions

DRUG

to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection

to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection

Sponsors & Collaborators

  • Shifa Ul Mulk Memorial Hospital

    lead OTHER

Principal Investigators

  • Misbah Ahmed, BEMS · Jinnah University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-12
Primary Completion
2024-08-12
Completion
2024-08-12

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05572268 on ClinicalTrials.gov